At Samso, we often talk about “first movers” and “market makers” in the mining and tech sectors. But when it comes to mental health care, particularly treatment-resistant conditions like Post-traumatic stress disorder (PTSD), the stakes aren’t just commercial. They’re deeply personal.

Emyria Limited (ASX: EMD) embodies the fusion of compassionate care, groundbreaking science, and a market in dire need of change. Recently, the company has gained attention by uniquely creating a scalable, evidence-based model for psychedelic-assisted therapy within licensed medical settings in Australia.